Skip to main content
SpringerLink
Log in

Roflumilast bei symptomatischer COPD

Eine neue medikamentöse Therapieoption?

Roflumilast for symptomatic COPD

A new medicinal therapy option?

  • Journal Club
  • Published:
Der Pneumologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehungen hin: Referententätigkeit für die Firmen Hoffmann-La Roche, Glaxo, Astra, Boehringer Ingelheim, Novartis, Merck Sharp & Dohme.

Author information

Authors and Affiliations

  1. Kardiologie, Pneumologie, Onkologie und internistische Intensivmedizin, Asklepios Klinik Wandsbek, Akademisches Lehrkrankenhaus der Universität Hamburg, Alphonsstr. 14, 22043, Hamburg, Deutschland

    J. Braun

Authors
  1. J. Braun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Braun.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Braun, J. Roflumilast bei symptomatischer COPD. Pneumologe 7, 125–127 (2010). https://doi.org/10.1007/s10405-009-0364-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10405-009-0364-7

Search

Navigation